In this cohort study of 1552 patients with non–small cell lung cancer, the group with high tumor mutation burden (TMB) had improved response rates and survival after receiving programmed cell death–1/programmed death ligand–1 (PD-L1) inhibition therapy across PD-L1 expression subgroups compared with the group with low TMB.
[JAMA Oncology]